Background

Zygotron Metadynamics is an international biotechnology company focused on the discovery, development and commercialisation of bone-marrow derived therapy for all forms of disease, with special focus on heart diseases.

Products

Our pipeline of breakthrough products includes research programmes and product candidates targeting the high dollar-value unmet medical needs of heart failure and myocardial infarction, where large groups of patients have poor outcomes despite powerful medical therapy developed through traditional means.

We have unique leverage through MyoThrive(R) developed through decades of work in Dusseldorf which allows bone marrow derived stem cells to differentiate, integrate and function in the myocardium.

Note that compared to the baseline appearance (upper panel), by 6 weeks after treatment (lower panel) there is improved fibre girth, better alignment and resolution of light-coloured lacunae. These high-clarity demonstrations from deep within the heart’s septum were only made possible by our patent-pending technology for transesophageal echocardiography first disclosed in 2005.

Profoundly ethical stance

We do no research on embryonic stem cells, and are compliant with devoted religious principles of all recognised religions.

“While human life is threatened in many ways in our society, the destruction of human embryos for stem-cell research confronts us with an issue of respect for life in a stark new way”

No animal research

Our transformational technology is now free of dependence on animal research. As summarised in an inspirational keynote by our chief medical advisor Prof Nemo Nikto,

The human being is a unique species: the degree of efficacy of the Zygotron concept in non-human animal models should not dissuade us from embarking on clinical trials in patients.